Chuter knows that, and almost didnt release Badder Boom because of it
While sommarutide is undoubtedly an exciting potential treatment option, there is still a lack of clear clinical data on the mechanism of action of GLP-1 agonists in NASH, such as whether GLP-1 agonists have a direct, independent role in improving NASH, or simply by improving body weight, insulin resistance, and so on
Every patient has signed the informed consent
Instead, they often peaked during titration and then levelled off, meaning that once participants were settled into their maintenance schedule, side effects tended to diminish rather than worsen
Researchers, particularly those engaged in Metabolic & Weight Research or even Mitochondrial Research initiatives, are increasingly exploring its potential
2025;388:e080952